The Cystic Fibrosis Foundation invested $150 million in a small biotechnology company to support development of new drugs to treat the deadly lung disease with which the Foundation is concerned. In 2014, the Foundation announced that it would receive $3.3 billion from selling the right to royalties related to the new drugs that were developed, an amount twenty times its annual budget. Some people said the investment helped produce needed new drugs and also fund future research. They said it should be a model for other disease-fighting nonprofits. Other people noted that use of one new drug would cost a patient $300,000 per year and said that the Foundation should have done more to push for lower prices. Critics argued that charities should support academic research but that it is a conflict of interest for an organization like the Cystic Fibrosis Foundation to invest in research by a company when it stands to gain financially. What is your opinion?